As we all know, the maker of EpiPen, Mylan, has engaged in price gouging. But this week, the larger health care industry sent a strong message that they are not going to stand for it. On Wednesday, Cigna announced it would only cover the generic version of EpiPen. On Thursday, CVS announced a deal with an EpiPen competitor that could hurt Mylan’s generic sales. It’s a strange and unusual kind of pushback. The kind we rarely see in the health care industry.
Click the above audio player to hear the full story.
20 hours ago26:01
20 hours ago25:42
a day ago6:54
a day ago8:03
4 days ago28:24
8 days ago25:04
8 days ago26:12
3 months ago12:30
4 months ago22:50
5 years ago20:58